Senseonics Holdings, Inc. Reports Third Quarter 2026 Financial Results

* Generated third quarter revenue of $19.6 million, an increase of approximately 140% year-over-year * Raised full-year 2026 revenue guidance to $68 million to $70 million from $62 million to $66 million, representing year-over-year growth of 93% to 98% * Achieved gross margin of approximately 62% during Q3, and raising full-year gross margin guidance to more than 60% from 58% to 61% GERMANTOWN, Md., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a diabetes company redefining continuous glucose monitoring (CGM) with long-term implantable sensing technology, today announced third quarter 2026 financial results and provided a business update.

Recent Highlights & Accomplishments * Drove third consecutive quarter of strong execution and performance since bringing U.S. Eversense® commercial operations in-house, delivering expansion of third quarter revenue to $19.6 million and gross margins to approximately 62% * U.S. third quarter revenue increased approximately 160% year-over-year to $16.8 million on record quarterly shipment volume, with active prescribers up approximately 90% year-over-year * Grew the EON Care network to more than 100 inserters, who performed over 40% of third quarter Eversense insertion procedures; increased the target goal of EON Care inserters to 120 by year-end * Announced a strategic partnership with Beta Bionics to integrate Eversense 365 with the iLet® Bionic Pancreas automated insulin delivery system to support continued growth into 2027, with commercial launch planned for the fourth quarter of 2026, subject to completion of integration activities and applicable requirements * Initiated the first-in-human study of Freedom, an investigational next-generation CGM system designed to communicate directly with a mobile device without any on-body component, building on the clinical experience and sensor technology shared with Eversense 365 and Gemini “Our approximately 140% year-over-year revenue growth in Q3 reflects the progress we are making in executing our commercial strategy and driving increased awareness and demand for Eversense 365,” stated Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. “Recent investments in commercial infrastructure are expanding patient access, supporting our growth and improving gross margins. We believe this infrastructure positions us to reach more patients as we expand pump compatibility and advance an innovative product pipeline designed to reduce device burden and offer greater convenience in everyday life. We are encouraged by the opportunities ahead and, given our continued momentum, are raising our full-year revenue outlook.”